Metallopanstimulin as a marker for head and neck cancer

Brendan C. Stack, Christopher S. Hollenbeak, Christopher M. Lee, Frank R. Dunphy, Val Lowe, Paul D. Hamilton

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts in the sera of patients with head and neck squamous cell carcinoma (HNSCC). We used a test, denoted MPS-H, which detects MPS-1 and MPS-1-like proteins, to determine the relationship between MPS-H serum levels and clinical status of patients with, or at risk for, HNSCC. Patients and methods: A total of 125 patients were prospectively enrolled from a university head and neck oncology clinic. Participants included only newly diagnosed HNSCC patients. Two control groups, including 25 non-smokers and 64 smokers, were studied for comparison. A total of 821 serum samples collected over a twenty-four month period were analyzed by the MPS-H radioimmunoassay. Results: HNSCC, non-smokers, and smokers had average MPS-H values of 41.5 ng/mL, 10.2 ng/mL, and 12.8 ng/mL, respectively (p = 0.0001). Conclusion: We conclude that MPS-1 and MPS-1-like proteins are elevated in patients with HNSCC, and that MPS-H appears to be a promising marker of presence of disease and response to treatment in HNSCC patients.

Original languageEnglish (US)
Article number45
JournalWorld Journal of Surgical Oncology
Volume2
DOIs
StatePublished - Dec 14 2004

Fingerprint

Head and Neck Neoplasms
Serum
Ribosomal Proteins
Radioimmunoassay
Carcinoma, squamous cell of head and neck
Proteins
Neck
Head
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Surgery

Cite this

Stack, B. C., Hollenbeak, C. S., Lee, C. M., Dunphy, F. R., Lowe, V., & Hamilton, P. D. (2004). Metallopanstimulin as a marker for head and neck cancer. World Journal of Surgical Oncology, 2, [45]. https://doi.org/10.1186/1477-7819-2-45

Metallopanstimulin as a marker for head and neck cancer. / Stack, Brendan C.; Hollenbeak, Christopher S.; Lee, Christopher M.; Dunphy, Frank R.; Lowe, Val; Hamilton, Paul D.

In: World Journal of Surgical Oncology, Vol. 2, 45, 14.12.2004.

Research output: Contribution to journalArticle

Stack, Brendan C. ; Hollenbeak, Christopher S. ; Lee, Christopher M. ; Dunphy, Frank R. ; Lowe, Val ; Hamilton, Paul D. / Metallopanstimulin as a marker for head and neck cancer. In: World Journal of Surgical Oncology. 2004 ; Vol. 2.
@article{c45fdf5bdc48498f97e43abb669a46f9,
title = "Metallopanstimulin as a marker for head and neck cancer",
abstract = "Background: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts in the sera of patients with head and neck squamous cell carcinoma (HNSCC). We used a test, denoted MPS-H, which detects MPS-1 and MPS-1-like proteins, to determine the relationship between MPS-H serum levels and clinical status of patients with, or at risk for, HNSCC. Patients and methods: A total of 125 patients were prospectively enrolled from a university head and neck oncology clinic. Participants included only newly diagnosed HNSCC patients. Two control groups, including 25 non-smokers and 64 smokers, were studied for comparison. A total of 821 serum samples collected over a twenty-four month period were analyzed by the MPS-H radioimmunoassay. Results: HNSCC, non-smokers, and smokers had average MPS-H values of 41.5 ng/mL, 10.2 ng/mL, and 12.8 ng/mL, respectively (p = 0.0001). Conclusion: We conclude that MPS-1 and MPS-1-like proteins are elevated in patients with HNSCC, and that MPS-H appears to be a promising marker of presence of disease and response to treatment in HNSCC patients.",
author = "Stack, {Brendan C.} and Hollenbeak, {Christopher S.} and Lee, {Christopher M.} and Dunphy, {Frank R.} and Val Lowe and Hamilton, {Paul D.}",
year = "2004",
month = "12",
day = "14",
doi = "10.1186/1477-7819-2-45",
language = "English (US)",
volume = "2",
journal = "World Journal of Surgical Oncology",
issn = "1477-7819",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Metallopanstimulin as a marker for head and neck cancer

AU - Stack, Brendan C.

AU - Hollenbeak, Christopher S.

AU - Lee, Christopher M.

AU - Dunphy, Frank R.

AU - Lowe, Val

AU - Hamilton, Paul D.

PY - 2004/12/14

Y1 - 2004/12/14

N2 - Background: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts in the sera of patients with head and neck squamous cell carcinoma (HNSCC). We used a test, denoted MPS-H, which detects MPS-1 and MPS-1-like proteins, to determine the relationship between MPS-H serum levels and clinical status of patients with, or at risk for, HNSCC. Patients and methods: A total of 125 patients were prospectively enrolled from a university head and neck oncology clinic. Participants included only newly diagnosed HNSCC patients. Two control groups, including 25 non-smokers and 64 smokers, were studied for comparison. A total of 821 serum samples collected over a twenty-four month period were analyzed by the MPS-H radioimmunoassay. Results: HNSCC, non-smokers, and smokers had average MPS-H values of 41.5 ng/mL, 10.2 ng/mL, and 12.8 ng/mL, respectively (p = 0.0001). Conclusion: We conclude that MPS-1 and MPS-1-like proteins are elevated in patients with HNSCC, and that MPS-H appears to be a promising marker of presence of disease and response to treatment in HNSCC patients.

AB - Background: Metallopanstimulin (MPS-1) is a ribosomal protein that is found in elevated amounts in the sera of patients with head and neck squamous cell carcinoma (HNSCC). We used a test, denoted MPS-H, which detects MPS-1 and MPS-1-like proteins, to determine the relationship between MPS-H serum levels and clinical status of patients with, or at risk for, HNSCC. Patients and methods: A total of 125 patients were prospectively enrolled from a university head and neck oncology clinic. Participants included only newly diagnosed HNSCC patients. Two control groups, including 25 non-smokers and 64 smokers, were studied for comparison. A total of 821 serum samples collected over a twenty-four month period were analyzed by the MPS-H radioimmunoassay. Results: HNSCC, non-smokers, and smokers had average MPS-H values of 41.5 ng/mL, 10.2 ng/mL, and 12.8 ng/mL, respectively (p = 0.0001). Conclusion: We conclude that MPS-1 and MPS-1-like proteins are elevated in patients with HNSCC, and that MPS-H appears to be a promising marker of presence of disease and response to treatment in HNSCC patients.

UR - http://www.scopus.com/inward/record.url?scp=13844297747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844297747&partnerID=8YFLogxK

U2 - 10.1186/1477-7819-2-45

DO - 10.1186/1477-7819-2-45

M3 - Article

VL - 2

JO - World Journal of Surgical Oncology

JF - World Journal of Surgical Oncology

SN - 1477-7819

M1 - 45

ER -